|
FDA 批准帕博利珠单抗 (Keytruda) 用于卡介苗治...
2020.01.08
FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
On January 8, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus C...
|
